List of Excipients in Branded Drug POMALIDOMIDE

Generic Drugs Containing POMALIDOMIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	pomalidomide	0480-4018	FERRIC OXIDE YELLOW
Teva Pharmaceuticals Inc	pomalidomide	0480-4018	FERROSOFERRIC OXIDE
Teva Pharmaceuticals Inc	pomalidomide	0480-4018	GELATIN
Teva Pharmaceuticals Inc	pomalidomide	0480-4018	MANNITOL

What are the Most Frequently-Used Excipients in POMALIDOMIDE?

# Of NDCs	Excipient
1	ALCOHOL
4	AMMONIA
1	ANHYDROUS LACTOSE
1	BUTYL ALCOHOL

Pomalidomide Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Pomalidomide is a high-value, low-dose oral immunomodulatory drug marketed by Bristol Myers Squibb as Pomalyst in multiple myeloma and AIDS-related Kaposi sarcoma. The commercial opportunity is concentrated in generic hard capsules, differentiated excipient systems, alternative oral dosage forms, and manufacturing technologies that improve content uniformity, containment, stability, and supply reliability. Pomalidomide is a small molecule, so biosimilar competition is irrelevant; the primary competitive pathway is abbreviated new drug application, or ANDA, approval.

What is the FDA status of pomalidomide?

The FDA approved Pomalyst capsules in February 2013 for patients with multiple myeloma who had received at least two prior therapies, including lenalidomide and bortezomib, and whose disease had progressed on or after the last therapy. FDA later approved pomalidomide with dexamethasone for adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy or in patients with HIV-negative disease.[1]

Item	Status
Active ingredient	Pomalidomide
Brand	Pomalyst
Sponsor	Celgene, now Bristol Myers Squibb
Dosage form	Oral hard gelatin capsule
Strengths	1 mg, 2 mg, 3 mg, and 4 mg
Primary therapeutic area	Relapsed or refractory multiple myeloma
Additional indication	AIDS-related Kaposi sarcoma
Regulatory pathway for generics	ANDA under section 505(j)
Biosimilar pathway	Not applicable
Risk controls	Pomalyst REMS and strict pregnancy-prevention requirements

Pomalidomide is a thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic activity. The low dose, high potency, teratogenicity, and narrow handling requirements shape the excipient and manufacturing strategy more than solubility alone.

What excipients are used in Pomalyst capsules?

The US prescribing information identifies a conventional immediate-release capsule platform. The core formulation uses lactose anhydrous, pregelatinized starch, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The capsule shell contains gelatin and titanium dioxide, with colorants varying by strength.[1]

Formulation function	Pomalyst excipient approach	Development implication
Diluent	Lactose anhydrous	Supports low-dose fill weight and powder handling
Binder/disintegrant	Pregelatinized starch	Supports capsule plug integrity and disintegration
Wetting agent	Sodium lauryl sulfate	Improves wetting of the active ingredient
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces segregation
Lubricant	Magnesium stearate	Supports capsule filling and ejection
Shell	Gelatin-based hard capsule	Standard commercial platform
Visual identification	Titanium dioxide and colorants	Reduces medication-error risk across strengths

The formulation is strategically important because pomalidomide is present at only 1 to 4 mg per capsule. The active ingredient can represent a small fraction of total blend weight. This creates a high content-uniformity burden and increases the impact of particle-size distribution, blend segregation, electrostatic charging, and transfer losses.

What excipient strategy is best for generic pomalidomide?

The strongest generic strategy is a conventional immediate-release capsule that closely matches the reference product’s critical quality attributes while avoiding unnecessary formulation innovation.

Content uniformity and low-dose blending

The central technical problem is uniform distribution of pomalidomide throughout the powder blend. A robust process can use:

• Controlled pomalidomide particle-size distribution
• Geometric dilution or ordered blending
• Preblending with a portion of lactose or starch
• Low-shear blending followed by validated lubrication
• In-process blend uniformity sampling
• Closed transfer systems to reduce powder loss
• Capsule-filling controls that limit weight variation

A carrier-based premix can reduce segregation, but it may create a process patent or trade-secret position if the premix ratio, order of addition, or particle engineering materially improves uniformity.

Excipient compatibility

Pomalidomide drug product development should evaluate:

• Moisture exposure
• Peroxide and aldehyde impurities in excipients
• Lubrication time and magnesium stearate concentration
• Capsule-shell brittleness
• Light exposure
• Thermal cycling
• Long-term storage at controlled room temperature

Anhydrous lactose is commercially attractive because it limits water introduction and aligns with the reference formulation. Lactose-free versions could target patients with intolerance or procurement requirements, but lactose substitution may require new bioequivalence work if dissolution, capsule fill, or powder behavior changes materially.

Powder containment

Pomalidomide is a potent and teratogenic active pharmaceutical ingredient. The excipient strategy must operate inside a containment system that manages operator exposure and cross-contamination.

Important controls include:

• Closed charging and discharge
• Isolators or contained weigh-and-dispense systems
• Dedicated or campaign-based equipment
• High-efficiency dust extraction
• Validated cleaning procedures
• Segregated packaging and waste handling
• Personnel controls consistent with the product’s reproductive-risk profile

The value proposition is not limited to the capsule formula. Equipment design, process containment, cleaning validation, and occupational hygiene can become material manufacturing differentiators.

What formulations are protected by pomalidomide patents?

Pomalidomide’s patent estate has historically included composition-of-matter, pharmaceutical-composition, method-of-use, and regulatory-exclusivity components. The original molecule and early thalidomide-analogue rights are largely distinct from later patents covering formulations, combinations, and treatment methods.

Protection category	Commercial relevance
Composition of matter	Controls the active molecule and limits early generic entry
Pharmaceutical composition	May cover excipient combinations, dosage forms, or release characteristics
Method of treatment	Can affect labeling, skinny-label strategy, and litigation exposure
Combination therapy	Relevant to pomalidomide plus dexamethasone or other agents
Manufacturing process	Can restrict specific synthetic or purification routes
Regulatory exclusivity	Delayed ANDA approval independently of patent status

The Orange Book is the controlling source for FDA-listed patents and pediatric-exclusivity information. Patent expiry must be assessed patent by patent because listed patents may have different expiration dates, terminal disclaimers, patent-term adjustments, and pediatric extensions.[2]

For excipient developers, the most relevant risk is usually not the existence of any lactose, starch, or magnesium stearate in a capsule. Broad, conventional excipient identities are difficult to protect commercially without a narrow formulation feature. Stronger claim opportunities typically involve:

• A defined particle-size distribution
• A specific active-to-carrier ratio
• A controlled agglomerate or granule
• A moisture-controlled capsule system
• A novel coating or shell
• A modified-release profile
• A stability improvement tied to a defined excipient combination
• A manufacturing sequence that produces a measurable performance advantage

When does pomalidomide lose exclusivity?

Pomalidomide’s major US regulatory exclusivities have expired. The remaining commercial barrier is patent-specific rather than a continuing new-chemical-entity or orphan-drug exclusivity block.

Exclusivity or protection	Approximate significance
New chemical entity exclusivity	Expired
Orphan-drug exclusivity for initial myeloma indication	Expired
FDA REMS requirements	Remain relevant to commercialization
Listed patents	Must be evaluated by patent and jurisdiction
Generic entry	Depends on ANDA approval, Paragraph IV litigation, settlements, and court outcomes

The practical entry date for a generic is determined by the earliest enforceable patent barrier, any 30-month litigation stay, the terms of settlement agreements, and the date awarded to a first applicant with a valid Paragraph IV challenge.

Which companies are challenging or competing with Pomalyst?

Pomalidomide faces two distinct competitive groups.

Generic pharmaceutical companies

Generic manufacturers can pursue 1 mg, 2 mg, 3 mg, and 4 mg capsules through ANDAs. Competitive advantages will depend on:

• Ability to satisfy bioequivalence requirements
• Access to controlled-substance-like containment infrastructure
• Reliable supply of pharmaceutical-grade pomalidomide
• Low-cost capsule filling
• REMS and risk-management compliance
• Launch timing under patent settlements
• Capacity to supply multiple strengths

The presence of four strengths increases manufacturing complexity but also creates opportunities for line rationalization, common-blend architecture, and flexible capsule-filling platforms.

Competing multiple myeloma products

Pomalidomide competes clinically with other immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, and emerging oral therapies. Lenalidomide is the closest mechanistic comparator, while newer regimens can displace pomalidomide in earlier treatment lines.

Drug	Company or major originator	Main competitive issue
Pomalidomide	Bristol Myers Squibb	Established relapsed-myeloma use; generic erosion risk
Lenalidomide	Bristol Myers Squibb	Earlier-line use and larger historical market
Thalidomide	Multiple suppliers	Older, less favored immunomodulatory option
Carfilzomib	Amgen	Proteasome-inhibitor alternative
Daratumumab	Johnson & Johnson/Genmab	Antibody-based regimen competition
Elotuzumab	Bristol Myers Squibb	Combination therapy alternative
Selinexor	XPOVIO, pharma partners	Oral mechanism and later-line competition

What generic entry risks exist for pomalidomide?

The principal generic-entry risks are regulatory, patent, manufacturing, and commercial.

Paragraph IV challenges

An ANDA applicant can certify that a listed patent is invalid, unenforceable, or not infringed under Paragraph IV. The reference sponsor can then file patent litigation, triggering a potential 30-month stay of FDA approval under the Hatch-Waxman Act.[3]

For pomalidomide, a challenger’s most important technical positions would likely involve:

• Non-infringement of formulation claims
• Invalidity based on prior art
• Lack of written description or enablement
• Obviousness of the claimed excipient combination
• Non-infringement through a different capsule composition
• A skinny-label strategy for patented indications

A generic applicant using the same immediate-release capsule architecture may reduce development risk but increase exposure to formulation claims. A materially different excipient system may reduce patent overlap but introduce bioequivalence and stability risk.

Settlement agreements

Pomalidomide settlements can authorize an agreed launch date before the final expiration of all listed patents. Commercial terms may include:

• Licensed entry date
• Authorized generic arrangements
• Restrictions by strength or indication
• Supply agreements
• No-challenge clauses
• Allocation of first-filer rights

Settlement terms must be assessed alongside the FDA’s Paragraph IV litigation record and the Orange Book. A settlement date can be commercially more important than the nominal patent expiry.

How strong is the pomalidomide patent estate?

The estate is stronger in commercial effect when it combines active-ingredient rights, treatment-method claims, formulation claims, and regulatory controls. Its practical strength is reduced as composition-of-matter and regulatory exclusivities expire and multiple generic manufacturers can use alternative excipient systems.

Patent-estate factor	Assessment
Active ingredient	Historically strong, but older rights have expired or approached expiry
Conventional capsule excipients	Generally moderate to weak unless tied to narrow performance claims
Method-of-use claims	Potentially relevant to labeled indications and skinny-label filings
Combination claims	Important where treatment regimens remain commercially differentiated
Manufacturing claims	Can create supply barriers if difficult to design around
REMS	Raises operational cost but does not create patent exclusivity
Generic design-around potential	Relatively high for conventional immediate-release capsules

The strongest new intellectual property opportunity is likely to involve an excipient-enabled performance improvement that can be demonstrated in stability, dissolution, manufacturability, or patient administration rather than a routine substitution of one diluent for another.

What excipient-based commercial opportunities exist?

Lactose-free and low-allergen capsules

A lactose-free capsule could address procurement and patient-preference segments. Candidate diluents include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starch systems. The formulation must preserve low-dose uniformity and comparable dissolution.

Improved flow and capsule-filling systems

A directly compressible or engineered carrier system could reduce blend segregation and improve high-speed capsule filling. Commercial value is highest if the process lowers rejection rates, reduces active loss, or permits a smaller manufacturing footprint.

Moisture-protective packaging

Pomalidomide capsules can be differentiated through high-barrier blister packaging, desiccant-enabled bottles, or unit-dose packaging. Packaging claims may be more practical than formulation claims when the objective is shelf-life extension or distribution into humid markets.

Pediatric or geriatric oral delivery

A dispersible, sprinkle, or liquid formulation could improve administration for patients unable to swallow capsules. The opportunity is constrained by teratogenicity, accidental exposure, dosing precision, and the need to prevent handling of open dosage forms by pregnant caregivers.

Modified-release formulations

Modified release could reduce peak-related toxicity or dosing frequency, but the commercial case is weaker than for immediate-release generics. Pomalidomide is administered at a low daily dose in established regimens, so a modified-release product would need a clear clinical or adherence advantage.

Combination and co-packaged products

Co-packaging pomalidomide with dexamethasone or regimen-specific medicines could improve adherence and pharmacy workflow. A true fixed-dose combination would face dose-flexibility problems because pomalidomide and partner drugs have different titration and scheduling requirements.

How does pomalidomide compare with lenalidomide for excipient opportunities?

Pomalidomide has a smaller dose range and a more concentrated opportunity around high-potency containment and low-dose blend uniformity. Lenalidomide has broader historical use and a larger generic market, but its commercial competition is also more mature.

Dimension	Pomalidomide	Lenalidomide
Typical capsule strengths	1-4 mg	Wider strength and dose flexibility
Main formulation issue	Very low-dose content uniformity	Broader dose and regimen complexity
Safety-management burden	High	High
Biosimilar relevance	None	None
Generic opportunity	Smaller but high-value niche	Larger, more crowded market
Differentiated excipient potential	Containment, uniformity, lactose-free systems	Dose flexibility, capsule efficiency, packaging

What is the revenue exposure to generic pomalidomide?

Pomalyst generated approximately $3.5 billion in worldwide revenue for Bristol Myers Squibb in 2023.[4] The product’s exposure to generic erosion is material because:

• The product has a high annual treatment cost relative to conventional oral generics.
• Multiple myeloma treatment is chronic and regimen-based.
• Four capsule strengths create recurring prescription volume.
• Generic price erosion can be rapid after multiple entrants.
• Specialty-pharmacy distribution and REMS controls can slow substitution but do not prevent it.

Revenue decline is likely to be more gradual if generic entry begins with limited strengths, licensed launches, or a small number of manufacturers. It is likely to accelerate when several ANDA applicants enter concurrently and payer formularies promote substitution.

What manufacturing and IP barriers matter most?

The key barriers are:

1. Secure supply of high-quality pomalidomide API.
2. Low-dose blend uniformity at commercial scale.
3. Potent-compound containment and cleaning validation.
4. Consistent capsule filling across four strengths.
5. Stability under global distribution conditions.
6. REMS-compliant distribution and pharmacovigilance.
7. Patent design-around capability.
8. Reliable production economics after price compression.

Geographic opportunities are strongest in the United States, Europe, Japan, and other markets with substantial relapsed-myeloma treatment. Emerging markets may favor lower-cost generic capsules but can impose local registration, serialization, and supply requirements. A lactose-free or heat- and humidity-tolerant product may have greater value in markets where storage and patient access are less predictable.

Key Takeaways

• Pomalidomide is a small-molecule product with generic, not biosimilar, competition.
• The reference product uses a conventional immediate-release hard-capsule formulation with lactose anhydrous, pregelatinized starch, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• Low-dose content uniformity, powder segregation, active loss, and containment are the main technical challenges.
• The best near-term commercial opportunity is a conventional ANDA capsule with strong process control and reliable multi-strength manufacturing.
• Higher-value opportunities include lactose-free excipient systems, improved powder engineering, moisture-protective packaging, and specialized oral delivery formats.
• Conventional excipient substitutions are unlikely to create strong standalone patent positions unless linked to measurable performance advantages.
• Pomalyst generated approximately $3.5 billion in worldwide revenue in 2023, creating significant generic-erosion exposure.
• FDA exclusivity has expired; patent-specific barriers, Paragraph IV litigation, settlements, and launch sequencing control market entry.
• REMS and teratogenicity requirements create operating costs for generic manufacturers but do not provide continuing market exclusivity.
• Excipient and manufacturing IP is most defensible when it improves uniformity, stability, containment, dissolution, or patient administration.

FAQs

Is pomalidomide a biologic that requires biosimilar competition?

No. Pomalidomide is a synthetic small molecule. Competitors generally pursue ANDAs for generic capsules rather than biosimilar applications.

Can a generic manufacturer use the same excipients as Pomalyst?

A generic manufacturer can use similar excipients if the product satisfies applicable FDA quality, bioequivalence, stability, labeling, and patent requirements. Similar excipient use does not eliminate potential formulation-patent exposure.

Is pomalidomide available as a tablet or injectable product?

Pomalyst is approved in the United States as an oral capsule. Tablets, liquids, dispersible products, and injectables would require separate development and regulatory approval.

Does the Pomalyst REMS prevent generic substitution?

No. REMS requirements impose distribution and risk-management obligations. They do not independently prevent FDA approval or pharmacy substitution of an approved generic.

Which excipient innovation has the highest commercial potential?

The most credible opportunity is an excipient and process system that improves low-dose content uniformity, powder containment, capsule-fill yield, or stability while maintaining immediate-release performance and a straightforward ANDA pathway.

References

1. U.S. Food and Drug Administration. (2024). Pomalyst (pomalidomide) capsules: Prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

4. Bristol Myers Squibb. (2024). 2023 annual report. Princeton, NJ: Bristol Myers Squibb.